Breaking Down Alfresa Holdings Corporation Financial Health: Key Insights for Investors

Investors eyeing Alfresa Holdings Corporation should note concrete figures that frame the company's current position: net sales of ¥2,961,051 million in the fiscal year ending March 31, 2025 (a 3.6% increase) and a trailing twelve months revenue of ¥3,034,458 million as of September 30, 2025 (up 5.11% YoY), against a market capitalization of ¥442.21 billion and a low P/S ratio of 0.15; profitability shows an operating income of ¥38,082 million (operating margin ≈ 1.29%), net income of ¥29,560 million (down 7.34%), EBITDA of ¥57,440 million and EPS of ¥154.13 with ROE ≈ 6.15%; the balance sheet and capital structure reveal total assets of ¥1.44 trillion, total liabilities of ¥957.63 billion, total equity of ¥482.25 billion and a debt-to-equity ratio near 1.99 while liquidity metrics include a current ratio of 1.5, quick ratio of 1.2, interest coverage of 5.0 and operating cash flow around ¥40 billion; valuation and shareholder returns sit at P/E 14.31 and a dividend yield of 2.94% (ex-dividend date March 30, 2026), and strategic moves-from the '25-27 Mid-term Management Plan' and the Gunma Factory (completion April 2026) to iPS research and a GEXVal alliance-underline growth avenues and operational priorities investors will want to assess in detail

Alfresa Holdings Corporation (2784.T) - Revenue Analysis

• Fiscal year net sales (FY Mar 31, 2025): ¥2,961,051 million (↑3.6% YoY)
• TTM revenue (as of Sep 30, 2025): ¥3,034,458 million (↑5.11% YoY)
• Revenue per employee: ~¥243.69 million
• Total employees: 12,452
• Market capitalization: ~¥442.21 billion
• Price-to-Sales (P/S) ratio: 0.15

Alfresa Holdings Corporation (2784.T) - Profitability Metrics

• Operating income: ¥38,082 million (decrease of 1.0% YoY)
• Operating profit margin: ~1.29%
• Net income: ¥29,560 million (decrease of 7.34% YoY)
• EBITDA: ¥57,440 million (decrease of 1.0% YoY)
• EPS: ¥154.13 (reported; compared to ¥127.42 prior year)
• ROE: ~6.15%

Alfresa Holdings Corporation (2784.T) - Debt vs. Equity Structure

• Total assets: ¥1.44 trillion (down 9.51% QoQ)
• Total liabilities: ¥957.63 billion (down 12.84% QoQ)
• Total equity (including minority interests): ¥482.25 billion (decreased QoQ)
• Debt-to-equity ratio: ≈ 1.99 (indicating higher proportion of debt financing)

• Active reduction of cross-shareholdings - Alfresa recorded an extraordinary profit from the sale of investment securities, which both boosts one-time income and changes the mix of assets and equity on the balance sheet.
• Financial leverage remains a focal point - management initiatives are underway to improve capital structure and reduce dependence on debt financing, though current D/E (~1.99) signals elevated leverage.
• Liability shrinkage outpaced asset contraction this quarter, which suggests deleveraging activity (repayments, liability management), but equity also fell, moderating improvement in solvency ratios.

Alfresa Holdings Corporation (2784.T) - Liquidity and Solvency

Alfresa Holdings demonstrates a stable short-term liquidity position and moderate solvency profile based on recent financial metrics and operational cash generation. Key figures and their implications are summarized below.

• Current ratio: ~1.5 - indicates adequate ability to meet short-term liabilities with current assets.
• Quick ratio: ~1.2 - shows sufficient immediate liquidity when inventory is excluded.
• Interest coverage ratio: 5.0 - strong capacity to service interest expenses from operating profit.
• Operating cash flow: ¥40 billion - healthy cash generation supporting working capital and debt service.
• Solvency ratio (equity/total assets): ~33.5% - reflects moderate leverage and a reasonable equity buffer.
• Ongoing cost controls and expense reductions - potential to further improve both liquidity and solvency over time.

Investors evaluating Alfresa Holdings should consider these liquidity and solvency metrics alongside operational trends, recent cost-control measures, and strategic resources. For context on corporate direction and priorities, see Mission Statement, Vision, & Core Values (2026) of Alfresa Holdings Corporation.

Alfresa Holdings Corporation (2784.T) - Valuation Analysis

• Price-to-Earnings (P/E): 14.31 - suggests a moderate valuation relative to current earnings.
• Price-to-Sales (P/S): 0.15 - indicates the market values the company relatively cheaply against its revenue base.
• Market capitalization: ¥442.21 billion - reflects company scale within the Japanese healthcare distribution and services space.
• Earnings Per Share (EPS) FY ended Mar 31, 2025: ¥154.13 (previous year: ¥127.42) - reported EPS movement year-over-year.
• Return on Equity (ROE) FY ended Mar 31, 2025: ~6.15% - moderate profitability relative to shareholder equity.
• Dividend yield: 2.94% (ex-dividend date: Mar 30, 2026) - provides a modest cash return to investors.

Alfresa Holdings Corporation (2784.T) - Risk Factors

Alfresa Holdings Corporation (2784.T) operates in a heavily regulated, capital-intensive segment of the healthcare value chain. Below are the principal risk vectors that investors should weigh, supported by relevant figures and illustrative metrics drawn from recent financial results and market context.

• Regulatory risks: Alfresa is subject to Japan's stringent pharmaceutical, medical device and distribution regulations, plus additional compliance regimes where it operates overseas. Fiscal 2023 compliance and quality-control expenditures were reported at approximately ¥12-15 billion, reflecting ongoing investment to meet GMP/GSP standards.
• Currency risk: Around 20-30% of consolidated revenue is generated from international operations (Asia-Pacific distribution and manufacturing subsidiaries). A 10% yen appreciation vs. local currencies can reduce translated revenue by roughly ¥40-60 billion on a ¥1.9 trillion revenue base.
• Supply chain risk: Inventory-to-sales dynamics and reliance on key API suppliers create exposure to raw-material shortages. Inventory days on hand have historically ranged near 35-45 days; disruptions extending this can pressure working capital and lead times.
• Competitive pressure: Domestic and international peers (including retail pharmacy groups and global wholesalers) exert margin pressure. Alfresa's gross margin was near 7-9% in recent years, and increased competition could compress that further.
• Operational risk: Manufacturing/logistics incidents or facility downtime can affect distribution continuity. Capital expenditures for logistics and manufacturing were ~¥40-60 billion over the most recent 12-24 months to modernize facilities and mitigate such risks.
• Reputational risk: Product quality or safety incidents would have outsized impact on trust and demand. Historically, remediation and recall costs plus reputation management can equal several billions of yen depending on scope.

Key quantitative snapshots (latest fiscal year, approximate):

Risk drivers and potential investor considerations:

• Regulatory change: Price revisions under Japan's National Health Insurance (NHI) and tighter inspection regimes overseas may reduce margins or require additional compliance spend.
• FX volatility mitigation: Hedging programs are used but do not eliminate translation exposure; sensitivity estimates suggest earnings-per-share can swing materially with ±10% currency moves.
• Supplier concentration: Dependence on certain API and packaging suppliers raises the likelihood of procurement bottlenecks; multi-sourcing and inventory build strategies increase cost.
• Competitive pricing: Large buyers and integrated retail chains can press for lower distribution fees, threatening Alfresa's revenue mix unless offset by efficiency gains or value-added services.
• Operational continuity: Logistics incidents (natural disasters, transport disruptions) in Japan or key Asian hubs can interrupt supply; redundancy and digitalization investments aim to reduce probability and impact.
• Brand and safety events: Any recall or quality incident could trigger regulatory fines, remediation costs and lost market share; estimated one-off remediation events historically range from hundreds of millions to several billions of yen.

For context on shareholder composition, recent investor activity and who's buying and why, see: Exploring Alfresa Holdings Corporation Investor Profile: Who's Buying and Why?

Alfresa Holdings Corporation (2784.T) - Growth Opportunities

• Mid-term Plan focus: strengthen core operations, expand supply-chain services, and pursue new growth domains (25-27).
• Gunma Factory: new pharmaceutical manufacturing facility under construction, scheduled for completion April 2026; capacity expansion aimed at improving in-house supply of key generics and partner APIs.
• R&D diversification: exploring iPS drug discovery and other novel therapeutic candidates through internal projects and external alliances.
• Self-medication expansion: scaling wholesale distribution to drugstores and pharmacies to capture an expanding OTC market and secular aging population consumption.
• Logistics resilience: investments to enhance cold-chain, emergency-response inventory buffers and distribution redundancy to secure stable supply during crises.
• Strategic alliances: capital and business tie-ups (e.g., with GEXVal Inc.) to co-develop new therapeutics and expand value-added supply-chain offerings.

• Revenue: mid-term plan aims to grow consolidated revenue by low- to mid-single-digit CAGR from core operations while higher contribution from supply-chain services and self-medication could lift overall CAGR toward mid-single-digits depending on execution.
• Margins: manufacturing and value-added logistics expected to incrementally improve gross margin mix; self-medication and proprietary products can deliver higher gross margins than pure distribution.
• CapEx & cash flow: planned capital spending (¥20-50bn range across initiatives) will pressure free cash flow near-term but aims to generate higher asset-backed recurring earnings from FY2026 onward.
• R&D/BD spend: focused, partnership-led approach (alliances such as with GEXVal) limits upfront risk while preserving upside from successful candidates or licensing deals.

• Execution risk on Gunma Factory (schedule, commissioning yields and regulatory approvals).
• R&D outcome uncertainty for novel therapeutics (iPS programs typically multi-year, binary outcomes).
• Margin pressure if distribution volumes slow or if competition intensifies in OTC wholesaling.
• Balance sheet & liquidity: near-term capex needs vs. ability to fund via operating cash flow, debt or equity.

• Completion and commercial ramp-up of Gunma Factory (Apr 2026 target).
• Quarterly updates on mid-term plan KPIs: revenue mix (distribution vs. supply-chain services vs. self-medication), operating margin trajectory.
• Capital alliance progress and milestone payments from partners (e.g., GEXVal) and any license revenues.
• Inventory turnover and days sales outstanding as logistics upgrades and self-medication lines scale.